Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance

Nature

Volumn 437, Issue 7055, 2005, Pages 141-146

  Willimsky, Gerald ^a   Blankenstein, Thomas ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; IMMUNOLOGY; MATHEMATICAL MODELS; VIRUSES;

IMMUNE RESPONSE; T CELLS; T-CELL RECOGNITION;

TUMORS;

CANCER VACCINE; TUMOR SPECIFIC TRANSPLANTATION ANTIGEN; TUMOR VACCINE; BACTERIOPHAGE RECEPTOR; CRE RECOMBINASE; GAMMA INTERFERON; INTEGRASE; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VIRUS PROTEIN; VIRUS T ANTIGEN;

MEDICINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER; CANCER PREVENTION; CONTROLLED STUDY; DRUG EFFECT; GENE ACTIVATION; GRAFT REJECTION; HEALTH STATUS; HOST; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; LIFESPAN; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RECIPIENT; T LYMPHOCYTE; TUMOR; VACCINATION; ANIMAL; BLOOD; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; LACTOSE OPERON; METABOLISM; NEOPLASM; TRANSGENIC MOUSE;

ANIMALIA;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; ATTACHMENT SITES, MICROBIOLOGICAL; EPIGENESIS, GENETIC; IMMUNE TOLERANCE; INTEGRASES; INTERFERON TYPE II; LAC OPERON; MICE; MICE, TRANSGENIC; NEOPLASMS; ONCOGENES; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VIRAL PROTEINS;

EID: 24344436369     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature03954     Document Type: Article

References (29)

1. Burnet, M. Immunological factors in the process of carcinogenesis. Br. Med. Bull. 20, 154-158 (1964).
2. Klein, G. & Klein, E. Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumour evolution. Proc. Natl Acad. Sci. USA 74, 2121-2125 (1977).
3. Stutman, O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183, 534-536 (1974).
4. Prehn, R. T. Stimulatory effects of immune reactions upon the growths of untransplanted tumors. Cancer Res. 54, 908-914 (1994).
5. Klein, G., Sjogren, H. O., Klein, E. & Hellstrom, K. E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20, 1561-1572 (1960).
6. Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111 (2001).
7. Street, S. E., Trapani, J. A., MacGregor, D. & Smyth, M. J. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med. 196, 129-134 (2002).
8. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumour escape. Nature Immunol. 3, 991-998 (2002).
9. Blankenstein, T. & Qin, Z. Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance. Adv. Cancer Res. 90, 179-207 (2003).
10. Qin, Z. & Blankenstein, T. A cancer immunosurveillance controversy. Nature Immunol. 5, 3-4 (2004).
11. Johnson, L. et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111-1116 (2001).
12. Meuwissen, R., Jonkers, J. & Berns, A. Mouse models for sporadic cancer. Exp. Cell Res. 264, 100-110 (2001).
13. Adams, T. E., Alpert, S. & Hanahan, D. Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature 325, 223-228 (1987).
14. Schell, T. D., Knowles, B. B. & Tevethia, S. S. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Res. 60, 3002-3012 (2000).
15. Mullen, C. A., Urban, J. L., Van Waes, C., Rowley, D. A. & Schreiber, H. Multiple cancers. Tumor burden permits the outgrowth of other cancers. J. Exp. Med. 162, 1665-1682 (1985).
16. Beck, C., Schreiber, H. & Rowley, D. Role of TGF-beta in immune-evasion of cancer. Microsc. Res. Tech. 52, 387-395 (2001).
17. Gorelik, L. & Flavell, R. A. Transforming growth factor-beta in T-cell biology. Nature Rev. Immunol. 2, 46-53 (2002).
18. Enzler, T. et al. Deficiencies of GM-CSF and Interferon gamma link inflammation and cancer. J. Exp. Med. 197, 1213-1219 (2003).
19. Khong, H. T. & Restifo, N. P. Natural selection of tumour variants in the generation of 'tumour escape' phenotypes. Nature Immunol. 3, 999-1005 (2002).
20. Schreiber, H. in Fundamental Immunology 5th edn (ed. Paul, W.) 1557-1592 (Raven, Philadelphia, 2003).
21. Staveley-O'Carroll, K. et al. Induction of antigen-specific T cell anergy: An early event in the course of tumour progression. Proc. Natl Acad. Sci. USA 95, 1178-1183 (1998).
22. Lee, P. P. et al. Characterization of circulating T cells specific for tumour-associated antigens in melanoma patients. Nature Med. 5, 677-685 (1999).
23. Blankenstein, T. The role of tumour stroma in the interaction between tumour and immune system. Curr. Opin. Immunol. 17, 180-186 (2005).
24. + CTL to cause tumour eradication. J. Immunol. 173, 6753-6759 (2004).
25. Old, L. J., Boyse, E. A., Clarke, D. A. & Carswell, E. A. Antigenic properties of chemically-induced tumors. Ann. NY Acad. Sci. 101, 80-106 (1962).
26. Kripke, M. L. & Fisher, M. S. Immunologic parameters of ultraviolet carcinogenesis. J. Natl. Cancer Inst. 57, 211-215 (1976).
27. Sakai, K., Mitani, K. & Miyazaki, J. Efficient regulation of gene expression by adenovirus vector-mediated delivery of the CRE recombinase. Biochem. Biophys. Res. Commun. 217, 393-401 (1995).
28. Li, L. P., Schlag, P. M. & Blankenstein, T. Transient expression of SV 40 large T antigen by Cre/LoxP-mediated site- specific deletion in primary human tumour cells. Hum. Gene Ther. 8, 1695-1700 (1997).
29. Cayeux, S., Richter, G., Noffz, G., Dörken, B. & Blankenstein, T. Influence of gene-modified (IL-7, IL-4, and B7) tumour cell vaccines on tumour antigen presentation. J. Immunol. 158, 2834-2841 (1997).